RxDoctor Payments Data

Jeffrey Zollinger, DO

Pain Medicine · Sparks, NVNPI 1326242041

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Boston Scientific at 39.0% of the total.

$3,674in general payments, 2019–2025

Across 221 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Nevro Corp.$731
  • AbbVie$475
  • Amgen$226
  • Globus Medical$220
  • Pfizer$131
  • plus $459 from 10 others

What the payments were for

  • Food & beverage$3,674100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,674 in reported general payments places this provider in the 55th percentile of 101 pain medicine providers in Nevada.

See all pain medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$324,528
Medicare patients
348
Services billed
10,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen104$4,988
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen149$3,615
Gabapentin107$1,393
Morphine Sulfate ErMorphine Sulfate16$873
Tramadol Hcl165$793
Pregabalin23$446
Oxycodone Hcl24$327
Meloxicam30$71

Paid to pharmacies, not to this prescriber.

Other pain medicine in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →